PHENOCELL

Their core work

Phenocell is a French biotech SME that develops and supplies human cell-based models for disease research and pharmaceutical screening. Their core work involves building physiologically relevant cellular systems — likely including reprogrammed or differentiated human cells — that can replicate disease mechanisms in vitro, enabling safer and more predictive testing than animal models. In H2020, they contributed this cell-model expertise to projects targeting chronic autoimmune disease relapse mechanisms and neurodegenerative disease screening platforms. For drug developers and academic researchers, they function as a specialized provider of human cellular tools that sit between biological insight and translational application.

What they specialise in

How they've shifted over time

Both H2020 projects ran concurrently (2015–2020 and 2016–2019), making a strict early-to-late evolution difficult to identify within this dataset. What the data does reveal is a dual-track specialization: one track in autoimmune disease biology (inflammatory signatures, relapse, immunosenescence) and another in neurodegenerative disease modelling for screening. The absence of keywords for the second half of their project portfolio reflects missing metadata on CENSUS rather than a genuine thematic silence. The underlying trajectory appears consistent — cell-based tools applied to chronic, complex diseases with high unmet need in pharma.

Phenocell appears to be positioning itself as a cell-model provider for both immunology and CNS disease applications — a combination that makes them relevant to any consortium needing translational in vitro tools in high-priority therapeutic areas.

How they like to work

Phenocell has participated exclusively as a consortium partner across both projects, never taking on a coordinating role — consistent with a specialist SME that contributes a defined technical capability rather than leading scientific strategy. With 17 unique partners across 8 countries from just two projects, they operate within sizeable multi-partner consortia and appear comfortable in international collaborative settings. This suggests they bring a clear, contractable deliverable (cell models or biological data) that fits neatly into larger research programmes.

Phenocell has connected with 17 unique consortium partners across 8 countries through just two projects, indicating well-integrated participation in European research networks despite their small size. Their geographic spread across 8 countries suggests they have been part of genuinely pan-European consortia rather than regionally clustered partnerships.

What sets them apart

Phenocell occupies a rare niche as a private SME providing human cell-based models for two of the most commercially important disease areas — autoimmunity and neurodegeneration — within the same organization. Companies with relevant drug pipelines in CNS or immune diseases typically need external partners who can supply validated human cellular systems, and Phenocell's participation in both RELENT and CENSUS demonstrates they can serve that need in a research consortium context. Based in Grasse (France), outside the major biotech hubs, they may offer more accessible collaboration terms than larger platform providers.

Highlights from their portfolio

• RELENT
  The largest-funded project in Phenocell's portfolio (EUR 443,500), running a full five years and targeting one of the most clinically pressing problems in immunology — preventing relapses in chronic autoimmune conditions — with a mechanistic focus on immunosenescence and inflammatory pathway signatures.
• CENSUS
  Directly addresses the core of Phenocell's commercial proposition — building cell-based models for neurodegeneration screening — making it the clearest public signal of their platform technology and its intended pharmaceutical application.